Unknown

Dataset Information

0

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.


ABSTRACT: AIM:Clinical use of glucagon-like peptide-1 receptor agonists (GLP-1RA) is consistently associated with heart rate (HR) acceleration in type 2 diabetes patients. We explored the mechanisms underlying this potential safety concern. METHODS:Ten healthy overweight males (aged 20-27 years) were examined in an open label, crossover study. Automated oscillometric blood pressure measurements and finger photoplethysmography were performed throughout intravenous administration of placebo (saline 0.9%), exenatide (targeting therapeutic concentrations) and a combination of exenatide and the nitric oxide synthase inhibitor L-N(G) -monomethyl arginine (L-NMMA). Sympathetic nervous system (SNS) activity was measured by heart rate variability and rate-pressure product. RESULTS:Exenatide increased HR by a mean maximum of 6.8 (95% CI 1.7, 11.9) beats min(-1) (P < 0.05), systolic blood pressure (SBP) by 9.8 (95% CI 3.5, 16.1) mmHg (P < 0.01) and markers of SNS activity (P < 0.05). No changes in total peripheral resistance were observed. Increases in HR, SBP and sympathetic activity were preserved during concomitant L-NMMA infusion. CONCLUSIONS:Our data argue against exenatide-induced reflex tachycardia as a response to vasodilation and rather suggest the involvement of SNS activation in humans.

SUBMITTER: Smits MM 

PROVIDER: S-EPMC4799913 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.

Smits Mark M MM   Muskiet Marcel H A MH   Tonneijck Lennart L   Hoekstra Trynke T   Kramer Mark H H MH   Diamant Michaela M   van Raalte Daniël H DH  

British journal of clinical pharmacology 20160125 4


<h4>Aim</h4>Clinical use of glucagon-like peptide-1 receptor agonists (GLP-1RA) is consistently associated with heart rate (HR) acceleration in type 2 diabetes patients. We explored the mechanisms underlying this potential safety concern.<h4>Methods</h4>Ten healthy overweight males (aged 20-27 years) were examined in an open label, crossover study. Automated oscillometric blood pressure measurements and finger photoplethysmography were performed throughout intravenous administration of placebo (  ...[more]

Similar Datasets

| S-EPMC7212086 | biostudies-literature
| S-EPMC10359524 | biostudies-literature
| S-EPMC2941093 | biostudies-literature
| S-EPMC6115824 | biostudies-literature
| S-EPMC7117999 | biostudies-literature
| S-EPMC6525650 | biostudies-literature
| S-EPMC4367954 | biostudies-literature
| S-EPMC4586040 | biostudies-literature
| S-EPMC5028393 | biostudies-literature
| S-EPMC3081617 | biostudies-literature